Favipiravir clinical trials
Also written Avigan and T-705.
How each study uses favipiravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the favipiravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
58 studies that test it; most in 2020 (37)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 37 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 39
MDVI, LLC (5) · Institut National de la Santé Et de la Recherche Médicale, France (3) · University of Oxford (3) · Appili Therapeutics Inc. (2) · Promomed, LLC (2) · King Abdullah International Medical Research Center (2) · Peking University First Hospital (2) · Shin Poong Pharmaceutical Co. Ltd. (1)
Often tested with
Tested in the same studies.
Hydroxychloroquine (5) · Molnupiravir (4) · Nitazoxanide (3) · Remdesivir (2) · Nirmatrelvir and ritonavir drug combination (2) · Ribavirin (2) · Artesunate (1) · Amodiaquine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 1 in phase 3
Studies that test favipiravir, phase 3 first.
- Jun 2027ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyPhase 2/3 · Irrua Specialist Teaching Hospital
- Jan 2027Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Phase 2 · University of Oxford
- Jan 2027A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaPhase 2 · University of Oxford
- Jan 2027Assessing Antiviral Treatments in Early Symptomatic RSVPhase 2 · University of Oxford
- Mar 2027AGILE (Early Phase Platform Trial for COVID-19)Phase 1/2 · University of Liverpool
- Jun 2027Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy VolunteersPhase 1 · Institut National de la Santé Et de la Recherche Médicale, France
Studies
Open first, then newest update. How each study uses favipiravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 58
- UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHFRecruitingPhase 2Liverpool School of Tropical MedicineNCT06860334Written as FavipiravirHow we know
- AGILE (Early Phase Platform Trial for COVID-19)RecruitingPhase 1/2University of LiverpoolNCT04746183Written as FavipiravirHow we know
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaRecruitingPhase 2University of OxfordNCT05648448Written as FavipiravirHow we know
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as FavipiravirHow we know
- Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy VolunteersRecruitingPhase 1Institut National de la Santé Et de la Recherche Médicale, FranceNCT06024421Written as favipiravirHow we know
- ISTH/ANRS 0409s INTEGRATE Lassa Fever StudyRecruitingPhase 2/3Irrua Specialist Teaching HospitalNCT06212336Written as FavipiravirHow we know
- Assessing Antiviral Treatments in Early Symptomatic RSVRecruitingPhase 2University of OxfordNCT06488300Written as FavipiravirHow we know
- Efficacy of Favipiravir Against Ebola (JIKI)CompletedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02329054Written as FavipiravirHow we know
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19CompletedPhase 2Shin Poong Pharmaceutical Co. Ltd.NCT04532931Written as Favipiravir plus NitazoxanideHow we know
- Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the SemenTerminatedPhase 2Institut National de la Santé Et de la Recherche Médicale, FranceNCT02739477Written as FavipiravirHow we know
- The Prevent Severe COVID-19 (PRESECO) StudyCompletedPhase 3Appili Therapeutics Inc.NCT04600895Written as FavipiravirHow we know
- Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 PatientsCompletedPhase 4Mansoura University HospitalNCT05502081Written as FavipiravirHow we know
- Efficacy and Safety of Favipiravir in Covid-19 Patients in IndonesiaCompletedPhase 3Ina-RespondNCT04613271Written as FavipiravirHow we know
- Control of COVID-19 Outbreaks in Long Term CareTerminatedPhase 2Appili Therapeutics Inc.NCT04448119Written as FavipiravirHow we know
- Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa FeverCompletedPhase 2Bernhard Nocht Institute for Tropical MedicineNCT04907682Written as FavipiravirHow we know
- Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19CompletedPhase 3R-PharmNCT04501783Written as FavipiravirHow we know
- FLARE: Favipiravir +/- Lopinavir: A RCT of Early AntiviralsCompletedPhase 2University College, LondonNCT04499677Written as FavipiravirHow we know
- Clinical Trial of Favipiravir Treatment of Patients With COVID-19CompletedPhase 3University of PecsNCT04600999Written as FavipiravirHow we know
- Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19CompletedPhase 2Stanford UniversityNCT04346628Written as FavipiravirHow we know
- Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 AdultsTerminatedPhase 2Hospital General de México Dr. Eduardo LiceagaNCT04475991Written as Maraviroc+Favipiravir+CTHow we know
See all 58 studies that test favipiravir →
Given beside what is tested · 5 — favipiravir is usual care or a partner of the new treatment
- UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHFRecruitingPhase 1/2Liverpool School of Tropical MedicineNCT05940545Written as FavipiravirHow we know
- Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19CompletedPhase 2Coordinación de Investigación en Salud, MexicoNCT04918927Written as FavipiravirHow we know
- Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 PatientsCompletedPhase 3RAAS Nutritionals, LLCNCT05417997Written as FavipiravirHow we know
- Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma TherapyStatus unknownPhase 1/2Hayandra Peduli FoundationNCT04715360Written as AviganHow we know
- Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in NepalStatus unknownPhase 3Nepal Health Research CouncilNCT04694612Written as FavipiravirHow we know
As the comparator · 3 — what is tested is compared with favipiravir
- Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionTerminatedPhase 3PharmaMarNCT04784559Written as FavipiravirHow we know
- Efficacy and Safety of JT001 (VV116) Compared With FavipiravirTerminatedPhase 3Shanghai Vinnerna Biosciences Co., Ltd.NCT05279235Written as FavipiravirHow we know
- Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19Status unknownPhase 2/3The Scientific and Technological Research Council of TurkeyNCT04828564Written as FavipiravirHow we know
Codes
What other systems call favipiravir · ClinicalTrials.gg INT004464
- MeSH (NLM) C462182favipiravirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) EW5GL2X7E0FAVIPIRAVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q16934561favipiravirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81605FavipiravirOne source FDA
- DrugBank DB12466One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C462182 | favipiravir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | EW5GL2X7E0 | FAVIPIRAVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q16934561 | favipiravir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81605 | Favipiravir | One source FDA |
| DrugBank | DB12466 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.